Research presented at the EADV Spring Symposium 2021 investigated the link between gut bacteria and skin inflammation.

A study at AAD VMX 2021 presented data on possible association between sex, skin cancer medication, and dermatologic adverse events.

New data from a phase 3 study evaluating SGX301 for treatment of cutaneous T-cell lymphoma (CTCL) skin symptoms was recently presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX 2021).

A study presented at the American Academy of Dermatology Virtual Meeting Experience 2021 exhibited new safety and efficacy data for etrasimod as a potential treatment for atopic dermatitis.

Mark Lebwohl, MD, discusses his recent presentation from AAD VMX 2021 regarding new data for various biologics for the treatment of psoriasis.

According to study data recently presented at AAD VMX 2021, tofacitinib demonstrated positive results when being evaluated as a possible treatment for cutaneous sarcoidosis.

Regenerative medicine is still in its infancy, but patient demand and ease of use are growing its popularity among dermatologists. However, regulatory issues raise concerns.

Interim analysis of data from the ECZTEND study evaluating the long-term safety, efficacy, and tolerability of tralokinumab for treatment of atopic dermatitis was presented at AAD VMX 2021.

Catch up on all of the latest news coming out of the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021).

A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.

Deucravacitinib meets primary end points for treating moderate to severe psoriasis.

Revance presents 4 AAD VMX ePoster abstracts examining phase 3 study data for DAXI, and the impact of HA filler manufacturing technologies on HA chain degradation.

Artificial intelligence diagnostics are less accurate on skin of color than light skin, even when trained on equal numbers of images.

In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

A survey found a large proportion of dermatologists surveyed said their patients referenced video conferencing as the reason for seeking cosmetic consultation since the start of the pandemic.

In phase 3b data presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021 showed bimekizumab achieved superior levels of complete skin clearance compared to secukinumab for psoriasis.

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.

Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.

Experts in core dermatological specialties share their insights on the game-changing research and innovation that advancing skin disease management and patient care.